Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 7/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771932 | 0.92 | PDE4B (0.44) | PDE4BMEN1GMNNUSP2ALDH1A1 | |
| SCHEMBL4777777 | 0.91 | PDE4B (0.45) | PDE4BMEN1GMNNUSP2ALDH1A1 | |
| SCHEMBL4778003 | 0.90 | MEN1 (0.43) | MAT2APDE4BMEN1GMNNUSP2 | |
| SCHEMBL4842986 | 0.86 | MAT2A (0.41) | MAT2APDE4BMEN1GMNNUSP2 | |
| SCHEMBL4777743 | 0.86 | MAT2A (0.41) | MAT2APDE4BMEN1GMNNUSP2 | |
| SCHEMBL27682186 | 0.84 | MAT2A (0.36) | MAT2APDE4BMAPTTSHRNPSR1 | |
| SCHEMBL4777603 | 0.83 | PDE4B (0.43) | PDE4BMEN1GMNNUSP2ALDH1A1 | |
| SCHEMBL27682188 | 0.82 | SIGMAR1 (0.36) | MAT2APDE4BPSEN1PSEN2APH1B | |
| SCHEMBL27682255 | 0.82 | MAT2A (0.36) | MAT2APDE4BMAPTTSHRNPSR1 | |
| SCHEMBL4776080 | 0.82 | SIGMAR1 (0.36) | MAT2APDE4BPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459451-B2 | e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease | ASTELLAS PHARMA INC. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1763528-B1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1763528-A1 | PYRAZOLOPYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006004188-A1 | PYRAZOLOPYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004003-A1 | Pyrazolopyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004003-A1 | Pyrazolopyridine derivatives | PDE4A, PDE3B, PDE5A | MAT2A 3361/4885PDE4B 4/4885MEN1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.